Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 03 May 2018
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome; Neuroendocrine tumours
- Focus Pharmacokinetics
- 03 May 2018 According to the Lexicon Pharmaceuticals media release, company anticipate to initiate this trial in 2H of 2018.
- 10 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 30 Apr 2018.
- 07 Mar 2018 New trial record